AI Article Synopsis
- * The patient underwent induction chemotherapy with biweekly DCF therapy, which effectively shrank the tumor and reduced its infiltration into the tracheal membrane.
- * Following chemotherapy, the patient successfully had a radical surgery involving total laryngopharyngoesophagectomy and reconstruction, with positive outcomes in terms of the tumor's pathology and safety of the procedure.
Article Abstract
Cervical esophageal adenocarcinoma has a low incidence rate and its treatment involves various strategies. We report a patient with locally advanced cervical to upper esophageal adenocarcinoma who was able to undergo induction chemotherapy and radical surgery. A 55-year-old man was diagnosed with a poorly differentiated adenocarcinoma between the cervical and upper thoracic esophagus. The primary lesion had infiltrated into the tracheal membrane and had metastasized into the cervical lymph nodes. The initial diagnosis was T4bN1M1 stage IVB. The lower edge of the tumor was close to the tracheal bifurcation, making it difficult to create a longitudinal tracheal foramen during surgery. Therefore, when biweekly-DCF therapy was performed as induction chemotherapy, the tumor shrank sufficiently and its infiltration into the tracheal membrane decreased subsequently. We performed total laryngopharyngoesophagectomy with three-field lymph node dissection and reconstruction using free jejunal grafts and subtotal stomach via a posterior mediastinum route and a permanent tracheal foramen as a radical surgery. The pathological diagnosis was T2/MP, N1, and the effect of chemotherapy was grade 2. Cervical esophageal adenocarcinoma was rare, but technically reliable and safe oncologic surgery was possible after induction chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421492 | PMC |
| http://dx.doi.org/10.1007/s13691-021-00505-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.
Nat Cancer
January 2025
Cancer Systems Biology Laboratory, The Francis Crick Institute, London, UK.
CDKN2A is a tumor suppressor located in chromosome 9p21 and frequently lost in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). How CDKN2A and other 9p21 gene co-deletions affect EAC evolution remains understudied. We explored the effects of 9p21 loss in EACs and cancer progressor and non-progressor BEs with matched genomic, transcriptomic and clinical data.
View Article and Find Full Text PDFDistinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma.
Cancer Immunol Immunother
January 2025
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are distinct histological subtypes of esophageal cancer. The tumor microenvironment of each subtype significantly influences the efficacy of immunotherapy. However, the characteristics of the tumor microenvironments of both subtypes, as well as their specific impacts on immunotherapy outcomes, still require further elucidation.
View Article and Find Full Text PDFDeciphering the Prognostic Landscape of Esophageal Adenocarcinoma: A PANoptosis-Related Gene Signature.
J Cancer
January 2025
Department of Pathology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000, China.
Article Synopsis
- Esophageal adenocarcinoma (EAC) has low survival rates despite treatment advancements, so understanding molecular mechanisms and identifying prognostic markers is essential for better patient outcomes.
- A bioinformatics analysis identified 8 key PANoptosis-related genes (PRGs) to create a prognostic risk score model that outperformed traditional staging methods and was validated through multiple analyses, including gene expression profiling and immune infiltration assessment.
- The study utilized techniques like WGCNA and RT-qPCR to identify crucial hub genes, whose effects on EAC cell behavior were tested in vitro, ultimately leading to a novel prognostic nomogram that integrates clinical features for improved predictive accuracy.
Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma.
Sci Rep
December 2024
Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland.
The incidence of oesophageal adenocarcinoma (OAC) has risen six-fold in western countries over the last forty years but survival rates have only marginally improved. Hyperactivation of the PI3K-AKT-mTOR pathway is a common occurrence in OAC, driving cell survival, proliferation and resistance to chemotherapeutic agents. Inhibition of AKT has been explored as a treatment strategy with limited success and current inhibitors have failed to progress through clinical trials.
View Article and Find Full Text PDFFLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?
Expert Rev Clin Pharmacol
January 2025
Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!